Exercise mimetic is a label applied to compounds that switch on part of the metabolic response to endurance training without the training. It is a category of intent, not a shared mechanism. The four compounds most often given the name act on four unrelated targets, and every result behind the label is an animal result.
- Exercise mimetic is a category label, not a shared mechanism: the four compounds most often given it act on AMPK, the folate cycle, NNMT and the estrogen-related receptors respectively.
- The 2008 Salk paper that coined the phrase measured a 44 percent endurance increase in sedentary mice after four weeks of oral AICAR.
- MOTS-c does not bind AMPK; it blocks the folate cycle so that AICAR accumulates, and the accumulated AICAR activates AMPK.
- In the founding 5-Amino-1MQ work, food intake did not change, which is what distinguishes the proposed mechanism from an appetite effect.
- Every result behind this category is a cell or animal result. None of the four compounds has an approved product or a completed human trial.
The label names a wish, not a pathway
A compound gets called an exercise mimetic when a paper reports that it switches on some part of the metabolic response to endurance training in an animal that did not train. That is the whole of the definition. It says nothing about what the compound is, what it binds, or how it gets into a cell, and the four materials most often carrying the label do four unrelated things at the molecular level.
This matters when reading a supplier listing, because the label travels between compounds while the evidence does not. A result obtained with one exercise mimetic is routinely used to explain the appeal of another with a different target, a different chemistry and a different literature. The AMPK work from 2008 is still doing promotional duty for compounds discovered a decade later that never touch AMPK.
What follows is the four targets, what was actually measured against each one, and where each result stops. Three of the four compounds are in this catalogue. One is not, and the reason is worth stating plainly.
- AICAR: phosphorylated to ZMP, activates AMPK directly
- MOTS-c: blocks the folate cycle so AICAR accumulates, then AMPK
- 5-Amino-1MQ: blocks NNMT, raising intracellular NAD and SAM
- SLU-PP-332: activates the estrogen-related receptors, not stocked here
- Shared by all four: animal evidence only, no approved product
AMPK: AICAR, and the paper that started the category
AICAR is 5-aminoimidazole-4-carboxamide ribonucleotide, a nucleotide analogue rather than a peptide. Taken into a cell it is phosphorylated to ZMP, a molecule close enough to AMP that it activates AMP-activated protein kinase. AMPK is the cell's energy sensor and normally responds to a rising AMP-to-ATP ratio, which is to say to scarcity. AICAR produces that signal without the scarcity, and the cell's metabolism shifts toward oxidative pathways in response.
The result that made the compound famous came from the Salk Institute in 2008. Narkar and colleagues, publishing in Cell under the title AMPK and PPARdelta agonists are exercise mimetics, gave sedentary mice four weeks of oral AICAR and measured a 44 percent increase in treadmill running endurance against untreated animals. No training was involved. The paper is where the phrase in this article's title comes from.
Two things about that result are usually left out. It is four weeks, in mice, and nothing about longer exposure or another species follows from it. And AMPK is not a muscle switch. It is a master regulator active in essentially every tissue, so activating it pharmacologically is a systemic intervention whose signalling intersects with cell growth and survival pathways in directions that depend on the tissue. Sustained activation is not characterised.
There is also a compliance fact that belongs before a purchase rather than after it. AICAR is prohibited in sport by the World Anti-Doping Agency, a listing that followed directly from the 2008 paper. Anyone whose work touches tested athletes should know that before the vial arrives. One further practical note: because AICAR is a nucleotide analogue and not a peptide, the analytical methods appropriate to it are not the peptide methods used across most of this catalogue, and its certificate should be read on those terms.
The folate cycle: MOTS-c reaches AMPK the long way round
MOTS-c is a sixteen-residue peptide whose instructions sit inside a mitochondrial gene rather than in the cell nucleus, which is structurally unusual on its own. Its reported mechanism is indirect and specific, and it is the reason this compound and AICAR belong in the same discussion at all.
In the founding work, MOTS-c blocks the folate cycle and the purine synthesis attached to it. AICAR accumulates as a consequence, and AICAR is itself a natural activator of AMPK. So the route runs folate cycle, then AICAR, then AMPK. The peptide does not bind the sensor. It changes the concentration of a metabolite that does.
Lee and colleagues reported this in Cell Metabolism in 2015. Mice on a high-fat diet that received injected synthetic MOTS-c did not show the diet-driven weight gain and insulin resistance seen in untreated animals, and blocking AMPK partly removed the effect, which is the evidence that AMPK is a required step rather than something happening alongside. A 2018 paper from Kim and colleagues in the same journal reported the peptide moving into the nucleus under metabolic stress and acting on gene activity there.
The shape of the 2015 experiment is the part that gets lost. Mice received the peptide alongside the high-fat diet from the start, so what was measured is prevention. Whether anything already established can be reversed is a different question and that study did not ask it. Human data on MOTS-c is mostly observed association between blood levels and metabolic measures, which is not treatment. The field is young enough that explanations change between papers, so a claim resting on a single study should be read as provisional.
NNMT: 5-Amino-1MQ is in the same conversation for a different reason
5-amino-1-methylquinolinium is a small molecule, a methylquinolinium salt, and not a peptide either. It blocks an enzyme called NNMT, which tags nicotinamide with a methyl group using SAM as the source of that group. Both halves of that reaction are the point. The reaction consumes nicotinamide, a building block for NAD, and it consumes SAM, the cell's main methyl donor. NNMT is overactive in liver and white fat in obesity, so the proposal is that blocking it leaves more NAD and more SAM inside the cell.
Neelakantan and colleagues published the founding work in Biochemical Pharmacology in 2017. In cultured fat cells the inhibitors lowered the enzyme's product, raised NAD and SAM, and cut fat synthesis. In mice made obese by diet, a potent version reduced body weight, white fat mass, fat cell size and blood cholesterol, and food intake did not change. That last detail is what separates the proposed mechanism from an appetite effect, and it is the same distinction the ERR work below turns on.
A later programme complicates it usefully. Ruf and colleagues, in Scientific Reports in 2022, produced a tricyclic NNMT inhibitor that improved blood sugar handling in obese mice, and the same improvement appeared in mice bred without NNMT at all. An effect present when the target is absent points at something other than the target. The authors say so themselves. It is the kind of result that rarely survives into a product description.
One practical consequence of the chemistry: being a small molecule rather than a peptide, 5-Amino-1MQ dissolves, stores and tests differently from most of this catalogue, and its certificate should be read on small-molecule terms.
ERR: SLU-PP-332, and why it is not sold here
The compound that most recently attracted the label targets a fourth thing entirely. SLU-PP-332 activates the estrogen-related receptors, a group of proteins that switch on metabolic pathways in tissues with high energy demand such as muscle, heart and brain. ERRs are more active during exercise and have historically been difficult to activate with a drug.
The University of Florida announced results on 22 September 2023 from work led by Thomas Burris, a professor of pharmacy there, with colleagues at Washington University in St. Louis and Saint Louis University, published in the Journal of Pharmacology and Experimental Therapeutics. Obese mice treated twice daily for a month gained ten times less fat than untreated animals and lost 12 percent of body weight, while eating the same amount and not moving more. An earlier paper that March reported normal-weight mice running 70 percent longer and 45 percent further than untreated animals.
Burris described the compound as telling skeletal muscle to make the same changes seen during endurance training. The announcement is explicit about the stage: the next step is refining the structure, ideally into something orally available rather than injected, then testing for side effects in further animal models before any move toward human trials. No human trial has been completed.
SLU-PP-332 is not in this catalogue. It is a small molecule at an early preclinical stage with no established analytical reference material of the kind this catalogue's documentation standard depends on, and stocking a compound whose identity cannot be confirmed against a recognised standard would put a certificate on the site that could not be verified. It is listed elsewhere. Anyone comparing it with what is stocked here should know that the comparison is between a compound with two mouse papers and compounds with rather more literature and rather longer histories, which cuts in both directions.
What none of the four results establish
Every finding above was measured in a cell culture or an animal. None of the four compounds has an approved product or an established human use, and none of the studies described here was a human treatment study. Endurance measured on a mouse treadmill is a treadmill result in a mouse.
Three patterns recur across the four literatures and are worth naming because they survive into supplier copy intact. A prevention experiment gets described as a reversal. An effect measured at four weeks gets described without its duration. And a systemic intervention gets described as though it acted only on the tissue the researcher was interested in, when AMPK, NNMT and the ERRs are all active well beyond muscle.
The mechanisms themselves are real and well described. What is not established is what happens over longer exposure, in other species, or at any dose in a person, and the gap between a named pathway and a demonstrated outcome is where most of the marketing in this category lives.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Three of the four are not peptides, and the certificate shows it
The category label hides a chemistry split that decides what a certificate for any of these can actually say. MOTS-c is a peptide. AICAR is a nucleotide analogue. 5-Amino-1MQ and SLU-PP-332 are small molecules. Those are three different analytical worlds, and a supplier that treats them as one is telling you something about its documentation.
For the peptide, the methods are the ones this catalogue uses throughout. Identity comes from mass spectrometry, because the molecular weight of a sixteen-residue sequence is a specific number that a wrong sequence will miss. Purity comes from reversed-phase HPLC read as a share of detected peak area. The two answer different questions and neither substitutes for the other, which is covered in the purity and identity guide.
For the nucleotide analogue and the small molecules, that pairing is not the right one. A small molecule is more usually confirmed by nuclear magnetic resonance or by comparison against a reference standard of the same material, and its purity figure is calculated on a different basis. A certificate that reports a small molecule using peptide language has either been reformatted from a template or describes tests that were not the appropriate ones. Either way the document is worth less than it looks. The question worth putting to a supplier is simply which method established identity for this particular material, and a supplier who cannot answer that for a non-peptide has not thought about it.
There is a second, duller consequence. Storage and reconstitution differ by chemistry, so guidance written for a lyophilised peptide does not transfer to a quinolinium salt. When a listing carries one set of handling instructions across a mixed catalogue, that is the same reuse problem the mechanism claims have, showing up in a place where it is easier to check.
Reading a supplier listing in this category
Four checks separate a listing that describes a compound from one that sells an outcome, and each of them is answerable from the page itself in under a minute.
Ask which target the page names. A listing that says exercise mimetic and never names AMPK, NNMT or the ERRs is describing the category rather than the material, and that is usually because the same text has been reused across compounds that do not share a mechanism.
Ask what species the numbers come from. Percentages that appear without a model attached are almost always rodent results with the model removed, and removing it is what converts a measurement into a promise.
Ask whether the compound is a peptide at all. Three of the four here are not. AICAR is a nucleotide analogue, 5-Amino-1MQ and SLU-PP-332 are small molecules, and only MOTS-c is a peptide. That determines which analytical methods apply and therefore what a certificate for it should contain, which is the subject of the identity and purity guides linked below.
Ask what the page says is unknown. A listing that states no limitation has either not read the papers or has decided not to pass them on. The open questions in this category are not obscure. They are in the discussion section of every study cited on this page.
Common questions
What does exercise mimetic actually mean?
Do AICAR and MOTS-c work the same way?
Is SLU-PP-332 available as a research material here?
Are any of these compounds approved for anything?
Which of these are peptides?
More laboratory guides
Sources
- Narkar and colleagues, AMPK and PPARdelta agonists are exercise mimetics, Cell (2008). The Salk Institute paper that coined the phrase and reported the 44 percent endurance increase in sedentary mice. Its publication led directly to AICAR being added to anti-doping lists.
- Lee and colleagues, The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance, Cell Metabolism (2015). The paper identifying MOTS-c and the folate cycle to AICAR to AMPK route. Note the design: mice received the peptide alongside the high-fat diet from the start, so this is prevention rather than reversal.
- Kim and colleagues, The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression, Cell Metabolism (2018). Reports MOTS-c moving into the nucleus under metabolic stress and acting on gene activity there, which is unusual for something encoded in mitochondrial DNA.
- Neelakantan and colleagues, Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice, Biochemical Pharmacology (2017). The founding paper for the NNMT inhibitor class. Food intake did not change in the obese mice, which is what separates the proposed mechanism from an appetite effect.
- Ruf and colleagues, Novel tricyclic small molecule inhibitors of nicotinamide N-methyltransferase for the treatment of metabolic disorders, Scientific Reports (2022). A separate NNMT programme whose blood sugar improvement also appeared in mice bred without NNMT at all, which the authors say points to activity beyond the intended target.
- University of Florida News, Exercise-mimicking drug sheds weight, boosts muscle activity in mice (22 September 2023). The university announcement of the ERR work, carrying the figures quoted here and the explicit statement that the next step is further animal testing before any human trial.
